Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 190 entries
Sorted by: Best Match Show Resources per page
Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.

Journal of cellular biochemistry. Supplement

Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG.
PMID: 7616753
J Cell Biochem Suppl. 1994;20:55-62. doi: 10.1002/jcb.240560906.

At the National Cancer Institute, Division of Cancer Prevention and Control, the Chemoprevention Branch and Agent Development Committee develop strategies for efficiently identifying, procuring, and advancing the most promising drugs into clinical trials. Scientific expertise is applied at each...

Cite
Kelloff GJ, Crowell JA, Boone CW, et al. Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. J Cell Biochem Suppl. 1994;20:55-62doi: 10.1002/jcb.240560906.
Kelloff, G. J., Crowell, J. A., Boone, C. W., Steele, V. E., Lubet, R. A., Greenwald, P., Alberts, D. S., Covey, J. M., Doody, L. A., & Knapp, G. G. (1994). Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. Journal of cellular biochemistry. Supplement, 2055-62. https://doi.org/10.1002/jcb.240560906
Kelloff, G J, et al. "Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute." Journal of cellular biochemistry. Supplement vol. 20 (1994): 55-62. doi: https://doi.org/10.1002/jcb.240560906
Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG. Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. J Cell Biochem Suppl. 1994;20:55-62. doi: 10.1002/jcb.240560906. PMID: 7616753.
Copy Download .nbib Format: NLM
[Direct research on the development of new drugs from Chinese composite recipes].

Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

Du L, Yang S, Xu L.
PMID: 11789178
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Sep;20(9):698-9.

No abstract available.

Cite
Du L, Yang S, Xu L. [Direct research on the development of new drugs from Chinese composite recipes]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000;20(9):698-9
Du, L., Yang, S., & Xu, L. (2000). [Direct research on the development of new drugs from Chinese composite recipes]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 20(9), 698-9.
Du, L, et al. "[Direct research on the development of new drugs from Chinese composite recipes]." Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine vol. 20,9 (2000): 698-9.
Du L, Yang S, Xu L. [Direct research on the development of new drugs from Chinese composite recipes]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Sep;20(9):698-9. Chinese. PMID: 11789178.
Copy Download .nbib Format: NLM
An e-mail system for obtaining approval to use a restricted agent.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Conlin PR, Alexis G.
PMID: 10613371
Am J Health Syst Pharm. 1999 Dec 15;56(24):2535-7. doi: 10.1093/ajhp/56.24.2535.

Because of concerns over cost, proper patient selection, and prescribing patterns, pharmacy and therapeutics committees must be very selective about which new medications can be added to formularies and used in health systems. However, in the final analysis, many...

Cite
Conlin PR, Alexis G. An e-mail system for obtaining approval to use a restricted agent. Am J Health Syst Pharm. 1999;56(24):2535-7doi: 10.1093/ajhp/56.24.2535.
Conlin, P. R., & Alexis, G. (1999). An e-mail system for obtaining approval to use a restricted agent. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 56(24), 2535-7. https://doi.org/10.1093/ajhp/56.24.2535
Conlin, P R, and Alexis, G. "An e-mail system for obtaining approval to use a restricted agent." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol. 56,24 (1999): 2535-7. doi: https://doi.org/10.1093/ajhp/56.24.2535
Conlin PR, Alexis G. An e-mail system for obtaining approval to use a restricted agent. Am J Health Syst Pharm. 1999 Dec 15;56(24):2535-7. doi: 10.1093/ajhp/56.24.2535. PMID: 10613371.
Copy Download .nbib Format: NLM
Recap of FDA product approvals--2000.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Traynor K.
PMID: 11258167
Am J Health Syst Pharm. 2001 Mar 01;58(5):363, 366-8.

No abstract available.

Cite
Traynor K. Recap of FDA product approvals--2000. Am J Health Syst Pharm. 2001;58(5):363, 366-8
Traynor, K. (2001). Recap of FDA product approvals--2000. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 58(5), 363, 366-8.
Traynor, K. "Recap of FDA product approvals--2000." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol. 58,5 (2001): 363, 366-8.
Traynor K. Recap of FDA product approvals--2000. Am J Health Syst Pharm. 2001 Mar 01;58(5):363, 366-8. PMID: 11258167.
Copy Download .nbib Format: NLM
FDA consolidates review process for new pharmaceuticals.

FDA consumer

[No authors listed]
PMID: 12523280
FDA Consum. 2002 Nov-Dec;36(6):2.

No abstract available.

Cite
FDA consolidates review process for new pharmaceuticals. FDA Consum. 2002;36(6):2
(2002). FDA consolidates review process for new pharmaceuticals. FDA consumer, 36(6), 2.
"FDA consolidates review process for new pharmaceuticals." FDA consumer vol. 36,6 (2002): 2.
FDA consolidates review process for new pharmaceuticals. FDA Consum. 2002 Nov-Dec;36(6):2. PMID: 12523280.
Copy Download .nbib Format: NLM
The numbers game.

Nature reviews. Drug discovery

[No authors listed]
PMID: 12474850
Nat Rev Drug Discov. 2002 Dec;1(12):929. doi: 10.1038/nrd983.

No abstract available.

Cite
The numbers game. Nat Rev Drug Discov. 2002;1(12):929doi: 10.1038/nrd983.
(2002). The numbers game. Nature reviews. Drug discovery, 1(12), 929. https://doi.org/10.1038/nrd983
"The numbers game." Nature reviews. Drug discovery vol. 1,12 (2002): 929. doi: https://doi.org/10.1038/nrd983
The numbers game. Nat Rev Drug Discov. 2002 Dec;1(12):929. doi: 10.1038/nrd983. PMID: 12474850.
Copy Download .nbib Format: NLM
FDA publishes analysis of the pipeline problem.

Nature reviews. Drug discovery

Frantz S.
PMID: 15152628
Nat Rev Drug Discov. 2004 May;3(5):379. doi: 10.1038/nrd1404.

No abstract available.

Cite
Frantz S. FDA publishes analysis of the pipeline problem. Nat Rev Drug Discov. 2004;3(5):379doi: 10.1038/nrd1404.
Frantz, S. (2004). FDA publishes analysis of the pipeline problem. Nature reviews. Drug discovery, 3(5), 379. https://doi.org/10.1038/nrd1404
Frantz, Simon. "FDA publishes analysis of the pipeline problem." Nature reviews. Drug discovery vol. 3,5 (2004): 379. doi: https://doi.org/10.1038/nrd1404
Frantz S. FDA publishes analysis of the pipeline problem. Nat Rev Drug Discov. 2004 May;3(5):379. doi: 10.1038/nrd1404. PMID: 15152628.
Copy Download .nbib Format: NLM
Panel eases US drug approval process.

The Lancet. Oncology

Susman E.
PMID: 14974474
Lancet Oncol. 2004 Feb;5(2):71. doi: 10.1016/s1470-2045(04)01367-1.

No abstract available.

Cite
Susman E. Panel eases US drug approval process. Lancet Oncol. 2004;5(2):71doi: 10.1016/s1470-2045(04)01367-1.
Susman, E. (2004). Panel eases US drug approval process. The Lancet. Oncology, 5(2), 71. https://doi.org/10.1016/s1470-2045(04)01367-1
Susman, Edward. "Panel eases US drug approval process." The Lancet. Oncology vol. 5,2 (2004): 71. doi: https://doi.org/10.1016/s1470-2045(04)01367-1
Susman E. Panel eases US drug approval process. Lancet Oncol. 2004 Feb;5(2):71. doi: 10.1016/s1470-2045(04)01367-1. PMID: 14974474.
Copy Download .nbib Format: NLM
Pharmaceutical research and development.

Clinical therapeutics

McKercher PL.
PMID: 1468093
Clin Ther. 1992 Sep-Oct;14(5):760-4; discussion 759.

Some aspects of pharmaceutical research and development (R&D) are reviewed. The viability of major pharmaceutical manufacturers depends on their research and thus they commit substantial resources to R&D programs. Major pharmaceutical manufacturers in the United States employ about 40,000...

Cite
McKercher PL. Pharmaceutical research and development. Clin Ther. 1992;14(5):760-4; discussion 759
McKercher, P. L. (1992). Pharmaceutical research and development. Clinical therapeutics, 14(5), 760-4; discussion 759.
McKercher, P L. "Pharmaceutical research and development." Clinical therapeutics vol. 14,5 (1992): 760-4; discussion 759.
McKercher PL. Pharmaceutical research and development. Clin Ther. 1992 Sep-Oct;14(5):760-4; discussion 759. PMID: 1468093.
Copy Download .nbib Format: NLM
Drug delay and the FDA.

International journal of dermatology

Barranco VP.
PMID: 1399193
Int J Dermatol. 1992 Oct;31(10):691-2. doi: 10.1111/j.1365-4362.1992.tb01372.x.

No abstract available.

Cite
Barranco VP. Drug delay and the FDA. Int J Dermatol. 1992;31(10):691-2doi: 10.1111/j.1365-4362.1992.tb01372.x.
Barranco, V. P. (1992). Drug delay and the FDA. International journal of dermatology, 31(10), 691-2. https://doi.org/10.1111/j.1365-4362.1992.tb01372.x
Barranco, V P. "Drug delay and the FDA." International journal of dermatology vol. 31,10 (1992): 691-2. doi: https://doi.org/10.1111/j.1365-4362.1992.tb01372.x
Barranco VP. Drug delay and the FDA. Int J Dermatol. 1992 Oct;31(10):691-2. doi: 10.1111/j.1365-4362.1992.tb01372.x. PMID: 1399193.
Copy Download .nbib Format: NLM
FDA clears 26 new drugs for marketing in 1992.

American journal of hospital pharmacy

[No authors listed]
PMID: 8470670
Am J Hosp Pharm. 1993 Apr;50(4):578, 581.

No abstract available.

Cite
FDA clears 26 new drugs for marketing in 1992. Am J Hosp Pharm. 1993;50(4):578, 581
(1993). FDA clears 26 new drugs for marketing in 1992. American journal of hospital pharmacy, 50(4), 578, 581.
"FDA clears 26 new drugs for marketing in 1992." American journal of hospital pharmacy vol. 50,4 (1993): 578, 581.
FDA clears 26 new drugs for marketing in 1992. Am J Hosp Pharm. 1993 Apr;50(4):578, 581. PMID: 8470670.
Copy Download .nbib Format: NLM
New Drugs Approved in 2019.

The American journal of medicine

Ebied AM, Patel KH, Cooper-DeHoff RM.
PMID: 32145207
Am J Med. 2020 Jun;133(6):675-678. doi: 10.1016/j.amjmed.2020.01.030. Epub 2020 Mar 05.

In 2019, the US Food and Drug Administration (FDA) approved 48 novel drugs. Thirty of the 48 (62.5%) novel drug approvals were reviewed and approved through an expedited review pathway while 20 of the 48 (41.7%) were approved for...

Cite
Ebied AM, Patel KH, Cooper-DeHoff RM. New Drugs Approved in 2019. Am J Med. 2020;133(6):675-678doi: 10.1016/j.amjmed.2020.01.030.
Ebied, A. M., Patel, K. H., & Cooper-DeHoff, R. M. (2020). New Drugs Approved in 2019. The American journal of medicine, 133(6), 675-678. https://doi.org/10.1016/j.amjmed.2020.01.030
Ebied, Alex M, et al. "New Drugs Approved in 2019." The American journal of medicine vol. 133,6 (2020): 675-678. doi: https://doi.org/10.1016/j.amjmed.2020.01.030
Ebied AM, Patel KH, Cooper-DeHoff RM. New Drugs Approved in 2019. Am J Med. 2020 Jun;133(6):675-678. doi: 10.1016/j.amjmed.2020.01.030. Epub 2020 Mar 05. PMID: 32145207.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 190 entries